Cover Image
市場調查報告書

全球眼科相關的合作條件·契約

Global Ophthalmics Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 258786
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球眼科相關的合作條件·契約 Global Ophthalmics Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告提供全球眼科市場上企業合作的締結趨勢其內容(合作條件)相關分析,近幾年的企業合作/交易形勢背景及其特徵(各類型·各開發階段·各適應症),平均交易條件,代表性的資本交易概略,大醫藥品企業趨勢,近幾年的合作交易一覽及其詳細內容等資訊彙整,為您概述為以下內容。

執行摘要

第1章 簡介

第2章 眼科相關的交易趨勢

  • 簡介
  • 過去數年的眼科相關的合作趨勢
  • 大醫藥品企業的眼科相關的交易活動
  • 眼科相關的合作:交易的各類型
  • 眼科相關的合作:各開發階段
  • 眼科相關的合作:各適應症
  • 眼科相關的合作的平均交易條件
    • 交易總額 (headline values)
    • 預付款金
    • 階段性付款
    • 權利金費率

第3章 代表性的眼科相關資本交易

  • 簡介
  • 有代表性的資本交易:各金額

第4章 大醫藥品企業的眼科相關的資本交易

  • 簡介
  • 大醫藥品企業的合作交易的活用法
  • 大醫藥品企業各公司簡介

第5章 眼科相關的合作契約的一覽

  • 簡介
  • 相關企業一覽
  • 交易的各類型
  • 各開發階段
  • 技術種類別

第6章 治療標靶別的交易

  • 簡介
  • 按治療標靶的資本交易

附錄

  • 附錄1 眼科相關的資本交易的一覽:企業名(A∼Z),總計7年份
  • 附錄2 眼科相關的資本交易的一覽:交易的各類型,總計7年份
  • 附錄3 眼科相關的資本交易的一覽:各開發階段,總計7年份
  • 附錄4 眼科相關的資本交易的一覽:技術種類別,總計7年份
  • 附錄5 合作資源中心
    • 線上合作
    • 合作相關活動
    • 相關調查
    • 交易的種類定義

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2219

The ‘Global Ophthalmics Partnering 2010-2016: Deal trends, players and financials’ report provides comprehensive understanding and unprecedented access to the ophthalmics partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Ophthalmics Partnering 2010 to 2016’ provides the full collection of Ophthalmics disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Ophthalmics partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Ophthalmics partnering agreement structure
  • Ophthalmics partnering contract documents
  • Top Ophthalmics deals by value
  • Most active Ophthalmics dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.

The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Ophthalmics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Ophthalmics dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Ophthalmics deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Ophthalmics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Ophthalmics deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Ophthalmics partnering deals by specific Ophthalmics target announced since 2010. The chapter is organized by specific Ophthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Ophthalmics partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Ophthalmics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Ophthalmics technologies and products.

Report scope

‘Global Ophthalmics Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Ophthalmics trends and structure of deals entered into by leading companies worldwide.

‘Global Ophthalmics Partnering 2010 to 2016’ includes:

  • Trends in Ophthalmics dealmaking in the biopharma industry since 2010
  • Analysis of Ophthalmics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Ophthalmics deal contract documents
  • Comprehensive access to over 3500 Ophthalmics deal records
  • The leading Ophthalmics deals by value since 2010
  • Most active Ophthalmics dealmakers since 2010

The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic retinopathy, Uveitis, plus other ophthalmic indications.

In ‘Global Ophthalmics Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Ophthalmics Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 400 ophthalmics deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Ophthalmics Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Ophthalmics deal trends since 2010
  • Access Ophthalmics deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Ophthalmics partner companies
  • Comprehensive access to over 750 links to actual Ophthalmics deals entered into by the world's biopharma companies
  • Indepth review of Ophthalmics deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Ophthalmics opportunities
  • Uncover companies actively partnering Ophthalmics opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Ophthalmics dealmaking

  • 2.1. Introduction
  • 2.2. Ophthalmics partnering over the years
  • 2.3. Ophthalmics partnering by deal type
  • 2.4. Ophthalmics partnering by industry sector
  • 2.5. Ophthalmics partnering by stage of development
  • 2.6. Ophthalmics partnering by technology type
  • 2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 -Financial deal terms for Ophthalmics partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Ophthalmics partnering
  • 3.3. Ophthalmics partnering headline values
  • 3.4. Ophthalmics deal upfront payments
  • 3.5. Ophthalmics deal milestone payments
  • 3.6. Ophthalmics royalty rates

Chapter 4 - Leading Ophthalmics deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Ophthalmics partnering
  • 4.3. List of most active dealmakers in Ophthalmics
  • 4.4. Top Ophthalmics deals by value

Chapter 5 - Ophthalmics contract document directory

  • 5.1. Introduction
  • 5.2. Ophthalmics partnering deals where contract document available

Chapter 6 - Ophthalmics dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Ophthalmics therapeutic target

Appendices

  • Appendix 1 - Directory of Ophthalmics deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Ophthalmics deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Ophthalmics deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Ophthalmics deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Ophthalmics partnering since 2010
  • Figure 2: Ophthalmics partnering by deal type since 2010
  • Figure 3: Ophthalmics partnering by industry sector since 2010
  • Figure 4: Ophthalmics partnering by stage of development since 2010
  • Figure 5: Ophthalmics partnering by technology type since 2010
  • Figure 6: Ophthalmics partnering by indication since 2010
  • Figure 7: Ophthalmics deals with a headline value
  • Figure 8: Ophthalmics deals with upfront payment values
  • Figure 9: Ophthalmics deals with milestone payment
  • Figure 10: Ophthalmics deals with royalty rates
  • Figure 11: Active Ophthalmics dealmaking activity- 2010 to 2016
  • Figure 12: Top Ophthalmics deals by value since 2010
Back to Top